SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-064861
Filing Date
2021-12-13
Accepted
2021-12-13 07:34:54
Documents
10
Period of Report
2021-12-13

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea152223-6k_biondvax.htm 6-K 11139
2 BIONDVAX PRESENTATION DATED DECEMBER 2021 ea152223ex99-1_biondvax.htm EX-99.1 11928
3 GRAPHIC ex99-1_001.jpg GRAPHIC 128454
4 GRAPHIC ex99-1_002.jpg GRAPHIC 412046
5 GRAPHIC ex99-1_003.jpg GRAPHIC 115426
6 GRAPHIC ex99-1_004.jpg GRAPHIC 140868
7 GRAPHIC ex99-1_005.jpg GRAPHIC 147382
8 GRAPHIC ex99-1_006.jpg GRAPHIC 203442
9 GRAPHIC ex99-1_007.jpg GRAPHIC 106975
10 GRAPHIC ex99-1_008.jpg GRAPHIC 160560
  Complete submission text file 0001213900-21-064861.txt   1974172
Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 211486967
SIC: 2836 Biological Products, (No Diagnostic Substances)